Medicare Enrolled
Dr. Erol Yorulmazoglu, M.D.
Hematology & Oncology · Elk Grove Village, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Yorulmazoglu from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Yorulmazoglu?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Yorulmazoglu
Dr. Erol Yorulmazoglu is a hematology & oncology specialist in Elk Grove Village, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Yorulmazoglu performed 40,150 Medicare services across 2,636 unique beneficiaries.
Between the years covered by Open Payments, Dr. Yorulmazoglu received a total of $5,764 from 60 pharmaceutical and/or device companies across 245 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Yorulmazoglu is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 24% volume in IL
$5,764 industry payments
Medicare Practice Summary
Medicare Utilization ↗40,150
Medicare services
Top 24% in IL for hematology & oncology
2,636
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,008 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
19,500 | $1 | $2 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
8,900 | $2 | $9 |
| Injection, granisetron, extended-release, 0.1 mg | 3,800 | $6 | $10 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,116 | $8 | $55 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
783 | $10 | $65 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
780 | $0 | $2 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
584 | $97 | $290 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
568 | $66 | $165 |
| Anti-nausea injection (ondansetron/Zofran) | 520 | $0 | $9 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
442 | $141 | $335 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
343 | $9 | $40 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
223 | $107 | $488 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
208 | $12 | $68 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
204 | $93 | $260 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
181 | $42 | $103 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
171 | $6 | $48 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
160 | $13 | $74 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
154 | $140 | $428 |
| Iron level test | 153 | $6 | $50 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
153 | $9 | $35 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
122 | $13 | $85 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
121 | $99 | $257 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
99 | $24 | $135 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
90 | $70 | $190 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
84 | $60 | $176 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
72 | $16 | $93 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 60 | $133 | $1,990 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
51 | $6 | $55 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
50 | $52 | $249 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
48 | $23 | $129 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
47 | $52 | $230 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
40 | $19 | $100 |
| PSA test (prostate cancer screening) | 35 | $18 | $97 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
31 | $28 | $114 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
31 | $118 | $390 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
28 | $15 | $80 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
28 | $26 | $189 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
28 | $1 | $6 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
27 | $3 | $10 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
26 | $109 | $328 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
25 | $2 | $17 |
| Phosphate level test A blood test that measures the amount of phosphate in your body. Phosphate is a mineral that helps keep bones and teeth strong. |
24 | $5 | $30 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
23 | $11 | $65 |
| New patient office visit, complex (60-74 min) | 17 | $170 | $495 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
49.7% high complexity
36.7% medium
13.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,764
Total received (2018-2024)
Avg $823/year across 7 years
Top 39% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
245
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,435 (94.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$329 (5.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,742
2023
$1,555
2022
$893
2021
$537
2020
$229
2019
$451
2018
$356
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$215
Gilead Sciences, Inc.
$137
Genentech USA, Inc.
$120
PFIZER INC.
$109
Merck Sharp & Dohme LLC
$109
Lilly USA, LLC
$104
Celgene Corporation
$95
Takeda Pharmaceuticals U.S.A., Inc.
$89
GENZYME CORPORATION
$69
Novartis Pharmaceuticals Corporation
$68
ABBVIE INC.
$62
E.R. Squibb & Sons, L.L.C.
$53
Janssen Biotech, Inc.
$45
GlaxoSmithKline, LLC.
$44
Alexion Pharmaceuticals, Inc.
$43
JAZZ PHARMACEUTICALS INC.
$36
Regeneron Healthcare Solutions, Inc.
$32
Kite Pharma, Inc.
$31
EMD Serono, Inc.
$27
Fennec Pharmaceuticals, Inc.
$27
Astellas Pharma US Inc
$27
Pharmacosmos Therapeutics Inc.
$25
PUMA BIOTECHNOLOGY, INC.
$25
Eisai Inc.
$24
Agios Pharmaceuticals, Inc.
$24
Incyte Corporation
$23
Mirati Therapeutics, Inc.
$22
ARRAY BIOPHARMA INC
$21
Adaptive Biotechnologies Corporation
$20
TAIHO ONCOLOGY, INC.
$17
Top 3 companies account for 27.1% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$650
AstraZeneca Pharmaceuticals LP
$456
Genentech USA, Inc.
$336
Lilly USA, LLC
$283
PFIZER INC.
$268
Celgene Corporation
$232
Seagen Inc.
$231
Merck Sharp & Dohme LLC
$202
Gilead Sciences, Inc.
$194
GENZYME CORPORATION
$191
Takeda Pharmaceuticals U.S.A., Inc.
$180
Pharmacyclics LLC, An AbbVie Company
$176
Regeneron Healthcare Solutions, Inc.
$170
Incyte Corporation
$164
Janssen Biotech, Inc.
$133
EMD Serono, Inc.
$128
Merck Sharp & Dohme Corporation
$125
GlaxoSmithKline, LLC.
$93
Amgen Inc.
$93
Eisai Inc.
$88
E.R. Squibb & Sons, L.L.C.
$86
JAZZ PHARMACEUTICALS INC.
$76
AbbVie Inc.
$75
Daiichi Sankyo Inc.
$68
Astellas Pharma US Inc
$64
ABBVIE INC.
$62
Kite Pharma, Inc.
$56
Inari Medical, Inc.
$54
Pharmacyclics LLC, an AbbVie Company
$53
Bayer Healthcare Pharmaceuticals Inc.
$50
Janssen Pharmaceuticals, Inc
$49
PUMA BIOTECHNOLOGY, INC.
$47
Coherus Biosciences Inc.
$43
Alexion Pharmaceuticals, Inc.
$43
Karyopharm Therapeutics Inc.
$41
Amneal Pharmaceuticals LLC
$30
Exelixis Inc.
$30
Fennec Pharmaceuticals, Inc.
$27
TerSera Therapeutics LLC
$26
SERVIER PHARMACEUTICALS LLC
$25
BeiGene USA, Inc.
$25
Pharmacosmos Therapeutics Inc.
$25
G1 Therapeutics, Inc.
$24
Agios Pharmaceuticals, Inc.
$24
Mirati Therapeutics, Inc.
$22
Verastem, Inc.
$22
ARRAY BIOPHARMA INC
$21
Adaptive Biotechnologies Corporation
$20
EISAI INC.
$19
Genmab U.S., Inc.
$18
TAIHO ONCOLOGY, INC.
$17
Taiho Oncology, Inc.
$16
Apellis Pharmaceuticals, Inc.
$16
Shire North American Group Inc
$16
MorphoSys, US Inc.
$16
AMAG Pharmaceuticals, Inc.
$15
Blueprint Medicines Corporation
$14
Jazz Pharmaceuticals Inc.
$13
Myriad Genetic Laboratories, Inc.
$13
Acrotech Biopharma LLC
$12
Top 3 companies account for 25.0% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ADYNOVATE · ALIMTA · ALUNBRIG · AVASTIN · Alecensa · BAVENCIO · BELEODAQ · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CHANTIX · COSELA · Copiktra · DARZALEX · ELAHERE · ELITEK · ELREXFIO · ENHERTU · ERLEADA · Empaveli · EndoPredict · Enhertu · Epkinly · FERAHEME · FLOWTRIEVER CATHETER · FRUZAQLA · Fabhalta · GAVRETO · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · Neulasta · Nplate · OJJAARA · OPDIVO · PADCEV · PEMAZYRE · PIQRAY · PROMACTA · PYRUKYND · Pedmark · Perjeta · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · S · SARCLISA · SCEMBLIX · SUTENT · Stivarga · TAGRISSO · TASIGNA · TEPMETKO · TUKYSA · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · XALKORI · XARELTO · XPOVIO · Xermelo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
288
Per 100K population
5.6
County median income
$81,797
Nearest hospital
ALEXIAN BROTHERS MEDICAL CENTER 1
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Yorulmazoglu is a mixed practice specialist, with above-average Medicare volume (top 24% in IL), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Yorulmazoglu experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Yorulmazoglu performed 19,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Yorulmazoglu receive payments from pharmaceutical companies?
Yes. Dr. Yorulmazoglu received a total of $5,764 from 60 companies across 245 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Yorulmazoglu's costs compare to other hematology & oncology specialists in Elk Grove Village?
Dr. Yorulmazoglu's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Yorulmazoglu) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Elk Grove Village
Browse hematology & oncology specialists in Elk Grove Village ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology